Lil­ly's Taltz wins third ap­proval, this time in pa­tients with ac­tive anky­los­ing spondyli­tis

Lil­ly’s mon­o­clon­al an­ti­body, Taltz, which is al­ready ap­proved for pso­ri­at­ic arthri­tis and plaque pso­ri­a­sis has won its third ap­proval. The FDA has cleared its use in ac­tive anky­los­ing spondyli­tis (AS), a chron­ic in­flam­ma­to­ry rheumat­ic dis­or­der that af­fects the pelvic joints and spine, and can be char­ac­ter­ized by in­flam­ma­to­ry back pain, stiff­ness and im­paired func­tion and mo­bil­i­ty.

Taltz — akin to No­var­tis’ $NVS block­buster Cosen­tyx — in­hibits IL-17A, a cy­tokine in­volved in in­flam­ma­to­ry and im­mune re­spons­es. The drug, which will now al­so ad­dress the rough­ly 1.6 mil­lion Amer­i­cans with AS, gen­er­at­ed about $354 mil­lion in the sec­ond quar­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.